



Antibacterial Activity and Global Reactivity Descriptors of some Newly Synthesized Unsymmetrical Sulfamides

AMEL BENDJEDDOU^{1*}, TAHAR ABBAZ^{1,3}, ADEL AYARI¹, MERZOUG BENAHMED²,
ABDELKRIM GOUASMIA³ and DIDIER VILLEMIN⁴

¹Laboratory of Aquatic and Terrestrial Ecosystems, Organic and Bioorganic Chemistry group, University of Souk Ahras, Algeria.

²Laboratory of Bioactive Molecules and Applications, University of Tebessa, Algeria.

³Laboratory of Organic Materials and Heterochemistry, University of Tebessa, Algeria.

⁴Laboratory of Molecular and Thio-Organic Chemistry, UMR CNRS 6507, INC3M, FR 3038, Labex EMC3, ensicaen & University of Caen, Caen 14050, France.

*Corresponding author E-mail: bendjeddouamel@gmail.com

<http://dx.doi.org/10.13005/ojc/320205>

(Received: February 03, 2016; Accepted: March 27, 2016)

ABSTRACT

In the present study a series of unsymmetric linear sulfamides (1-9) starting from a primary amine were synthesized and their structures were confirmed by elemental analyses, mass spectrometry and ¹H NMR techniques. All the synthesized compounds were screened for their antibacterial activities by both disc diffusion and minimal inhibition concentration (MIC) methods. Frontier molecular orbital (FMO) analysis and global reactivity descriptors have been performed using the density functional theory (DFT) with the B3LYP functional. The results indicated that these derivatives, depending of their substituted radical, bring about an improvement in the bacterial activity.

Keywords: Unsymmetric Sulfamides, Antibacterial Activity, Global Reactivity, Minimum Inhibitory Concentrations (MIC).

INTRODUCTION

Sulfonamides (sulfa drugs) were the first drugs largely employed and systematically used as preventive and chemotherapeutic agents against various diseases¹. They are active against a broad range of *Gram-positive* and *Gram-negative* bacteria and function as competitive antagonists to bacterial folate synthesis². They constitute an important class

of drugs, with several types of pharmacological activities including antibacterial³ anti-carbonic anhydrase⁴ diuretic⁵ hypoglycemic⁶ and antithyroid activity⁷. Sulfonamides were primarily developed as antibacterial agents, with sulfanilamide the first recognized sulfonamide antibacterial. Since then many other effective antibacterial derived from sulfonamides have been discovered and utilized in medicine. These classes of compounds are

considered as “scaffolds” in medicinal chemistry to drug development with different biological activities. In organic chemistry, these compounds have a functional application in the industry in some products of health, food colorants and others; therefore it is necessary to continue with research projects that help to synthesize new compounds with sulfonamide group.

In light of these, we became interested in the synthesis, characterization and biological evaluation of unsymmetric linear sulfamides. In order to assess more accurately and to provide a background frame work for the work described in this paper, a correlation between biological activity and some appropriate quantum descriptors⁸⁻⁹ such as E_{HOMO} , E_{LUMO} , energy gap, global hardness, global hardness softness, electrophilicity index and molecular electrostatic potential have also been carried out from the density functional theory (DFT).

EXPERIMENTAL

General

NMR spectra were recorded on a WP 400-NMR instrument. FAB mass spectra were recorded on a JOEL JMS-DX 300 spectrometer. Uncorrected melting points were measured on a 510 Buchi apparatus. Density functional theory calculations were carried out using the Gaussian 09W program packages developed by Frisch and coworkers¹⁰. The Becke's three parameter hybrid functional using the LYP correlation functional (B3LYP), one of the most robust functional of the hybrid family, was herein used for all the calculations, with 6.31G (d, p) basis set¹¹⁻¹². Gaussian output files were visualized by means of gaussian view 05 software¹³. All solvents were dried by standard methods and all commercial reagents used without purification. All reactions were performed under an inert atmosphere of nitrogen.

Inhibition zones (DZI) of the compounds were examined by disc diffusion technique¹⁴⁻¹⁵. The Antibacterial screening was performed using Mueller–Hinton agar for 24 hrs at 37°C. After incubation, the zone of growth inhibition around the disks was measured in millimeter (mm). All tests were performed in duplicate, and experiment was repeated three times.

Minimum Inhibitory Concentrations (MICs) values, defined as the lowest concentration of sample which inhibits the visible growth of microorganism after overnight incubation, were also determined by the broth dilution method following the procedures recommended by the CLSI (Clinical and Laboratory Standards Institute)¹⁴.

Synthesis and Characterization of unsymmetrical sulfamides 1-9

A solution of sulfonyl chloride (1 equiv, 10 mmol, 1.35 g) in hexane (30 ml) was added dropwise to a stirred solution of the first amine (1 equiv, 10 mmol) and the second amine (1 equiv, 10 mmol) in hexane (80 ml) cooled to 0°C. The reaction mixture was stirred for 6h, then it was extracted with CH_2Cl_2 (200 ml), the organic phase was washed with 120 ml of 1M HCl, followed with water (120 ml), and dried with Na_2SO_4 and the solvent was removed under reduced pressure to give the crude as colorless oil. Compounds 1-9 were obtained by column chromatography of the residue (silica gel, eluting with (AcOEt / *n*-Hexane: 6/4).

N-(thiophen-2-yl methyl)-N'-(tert-butyl) sulfamide 1

Beige powder. Yield: 25%. M.p.: 155°C. TLC: Rf = 0.74 (AcOEt / *n*-Hexane: 6/4). ¹H NMR (400 MHz, CDCl_3 , δ , ppm): 1.40 (s, 9H, tBu); 3.93 (s, 2H, CH_2 -N-thio); 4.30 (s, 1H, NH-tBu); 4.45 (s, 1H, NH-thio); 6.63 (d, 1H, J = 3.60 Hz, thio); 6.75 (t, 1H, J = 4.45 Hz, thio); 6.95 (d, 1H, J = 4.45 Hz, thio). MS (NOBA, FAB > 0): 627 [M + H]⁺. Anal. calcd for $\text{C}_9\text{H}_{16}\text{N}_2\text{O}_2\text{S}_2$: C, 43.52%; H, 6.49%; S, 25.82%; found: C, 43.67%; H, 6.59%; S, 25.60%.

N-(thiophen-2-yl methyl)-N'-(isopentyl) sulfamide 2

Beige powder. Yield: 28%. M.p.: 149°C. TLC: Rf = 0.80 (AcOEt / *n*-Hexane: 6/4). ¹H NMR (400 MHz, CDCl_3 , δ , ppm): 1.10 (d, 6H, 2 CH_3); 1.60 (m, 2H, CH_2); 1.90 (m, 1H, CH-(CH_3)₂); 2.75 (t, 2H, CH_2 -N); 4.26 (s, 1H, NH-isopro); 4.45 (s, 1H, NH-thio); 3.93 (s, 2H, CH_2 -N-thio); 6.63 (d, 1H, J = 3.60 Hz, thio); 6.75 (t, 1H, J = 4.45 Hz, thio); 6.95 (d, 1H, J = 4.45 Hz, thio). MS (NOBA, FAB > 0): 627 [M + H]⁺. Anal. calcd for $\text{C}_{10}\text{H}_{18}\text{N}_2\text{O}_2\text{S}_2$: C, 45.77%; H, 6.91%; S, 24.44%; found: C, 46.00%; H, 7.10%; S, 24.25%.

N-(thiophen-2-yl methyl)-N'-(isobutyl) sulfamide 3

Beige powder. Yield: 26%. M.p.: 151°C. TLC: R_f = 0.77 (AcOEt / *n*-Hexane: 6/4). ¹H NMR (400 MHz, CDCl₃, δ, ppm): 1.06 (d, 6H, 2CH₃); 2.00 (m, 1H, CH(CH₃)₂); 2.65 (d, 2H, CH₂-N); 3.93 (s, 2H, CH₂-N-thio); 4.28 (s, 1H, NH-*i*Bu); 4.45 (s, 1H, NH-thio); 6.63 (d, 1H, J = 3.60 Hz, thio); 6.75 (t, 1H, J = 4.45 Hz, thio); 6.95 (d, 1H, J = 4.45 Hz, thio). MS (NOBA, FAB > 0): 627 [M + H]⁺. Anal. calcd for C₉H₁₆N₂O₂S₂: C, 43.52%; H, 6.49%; S, 25.82%; found: C, 43.77%; H, 6.58%; S, 25.53%.

N-(pyridin-4-yl methyl)-N'-(tert-butyl) sulfamide 4

Scarcely green powder. Yield: 30%. M.p.: 147°C. TLC: R_f = 0.61 (AcOEt / *n*-Hexane: 6/4). ¹H NMR (400 MHz, CDCl₃, δ, ppm): 1.40 (s, 9H, *t*Bu); 3.96 (d, 2H, J = 4.66 Hz, CH₂-pyr); 4.30 (s, 1H, NH-*t*Bu); 4.50 (s, 1H, NH-pyr) 7.45 (d, 2H, J = 4.65 Hz, pyr); 8.72 (d, 2H, J = 4.68 Hz, pyr). MS (NOBA, FAB > 0): 627 [M + H]⁺. Anal. calcd for C₁₀H₁₇N₃O₂S: C, 49.36%; H, 7.04%; S, 13.17%; found: C, 49.60%; H, 7.17%; S, 13.25%.

N-(pyridin-4-yl methyl)-N'-(isopentyl) sulfamide 5

Scarcely green powder. Yield: 33%. M.p.: 142°C. TLC: R_f = 0.66 (AcOEt / *n*-Hexane: 6/4). ¹H NMR (400 MHz, CDCl₃, δ, ppm): 1.10 (d, 6H, 2CH₃); 1.60 (m, 2H, CH₂); 1.90 (m, 1H, CH-(CH₃)₂); 2.75 (t, 2H, CH₂-N); 3.96 (d, 2H, J = 4.66 Hz, CH₂-pyr); 4.26 (s, 1H, NH-isopro); 4.50 (s, 1H, NH-pyr) 7.45 (d, 2H, J = 4.65 Hz, pyr); 8.72 (d, 2H, J = 4.68 Hz, pyr). MS (NOBA, FAB > 0): 627 [M + H]⁺. Anal. calcd

for C₁₁H₁₉N₃O₂S: C, 51.33%; H, 7.44%; S, 12.46%; found: C, 51.48%; H, 7.59%; S, 12.61%.

N-(pyridin-4-yl methyl)-N'-(isobutyl)sulfamide 6


Scarcely green powder. Yield: 31%. M.p.: 145°C. TLC: R_f = 0.63 (AcOEt / *n*-Hexane: 6/4). ¹H NMR (400 MHz, CDCl₃, δ, ppm): 1.06 (d, 6H, 2CH₃); 2.00 (m, 1H, CH(CH₃)₂); 2.65 (d, 2H, CH₂-N); 3.96 (d, 2H, J = 4.66 Hz, CH₂-pyr); 4.28 (s, 1H, NH-*i*Bu); 4.50 (s, 1H, NH-pyr) 7.45 (d, 2H, J = 4.65 Hz, pyr); 8.72 (d, 2H, J = 4.68 Hz, pyr). MS (NOBA, FAB > 0): 627 [M + H]⁺. Anal. calcd for C₁₀H₁₇N₃O₂S: C, 49.36%; H, 7.04%; S, 13.17%; found: C, 49.51%; H, 7.15%; S, 13.22%.

N-(benzyl)-N'-(tert-butyl)sulfamide 7

White powder. Yield: 21%. M.p.: 136°C. TLC: R_f = 0.70 (AcOEt / *n*-Hexane: 6/4). ¹H NMR (400 MHz, CDCl₃, δ, ppm): 1.40 (s, 9H, *t*Bu); 4.15 (d, 2H, J = 5.99 Hz, CH₂-Ph); 4.30 (s, 1H, NH-*t*Bu); 4.47 (s, 1H, NH-Bn); 7.30 (m, 5H, ArH). MS (NOBA, FAB > 0): 627 [M + H]⁺. Anal. calcd for C₁₁H₁₈N₂O₂S: C, 54.51%; H, 7.48%; S, 13.23%; found: C, 54.67%; H, 7.59%; S, 13.35%.

N-(benzyl)-N'-(isopentyl)sulfamide 8

White powder. Yield: 24%. M.p.: 130°C. TLC: R_f = 0.75 (AcOEt / *n*-Hexane: 6/4). ¹H NMR (400 MHz, CDCl₃, δ, ppm): 1.10 (d, 6H, 2CH₃); 1.60 (m, 2H, CH₂); 1.90 (m, 1H, CH-(CH₃)₂); 2.75 (t, 2H, CH₂-N); 4.15 (d, 2H, J = 5.99 Hz, CH₂-Ph); 4.26 (s, 1H, NH-isopro); 4.47 (s, 1H, NH-Bn); 7.30 (m, 5H, ArH). MS (NOBA, FAB > 0): 627 [M + H]⁺. Anal. calcd for C₁₂H₂₀N₂O₂S: C, 56.22%; H, 7.86%; S, 12.50%; found: C, 56.33%; H, 8.02%; S, 12.43%.



R₁ = thiophen-2-yl methyl, pyridin-4-yl methyl, benzyl
R₂ = *tert*-butyl, isopentyl, isobutyl

1: R₁ = thiophen-2-yl methyl R₂ = *tert*-butyl
2: R₁ = thiophen-2-yl methyl R₂ = isopentyl
3: R₁ = thiophen-2-yl methyl R₂ = isobutyl
4: R₁ = pyridin-4-yl methyl R₂ = *tert*-butyl
5: R₁ = pyridin-4-yl methyl R₂ = isopentyl
6: R₁ = pyridin-4-yl methyl R₂ = isobutyl
7: R₁ = benzyl R₂ = *tert*-butyl
8: R₁ = benzyl R₂ = isopentyl
9: R₁ = benzyl R₂ = isobutyl

Scheme 1: Synthetic Route For The Preparation Of Dissymmetric Sulfamides Derivatives 1-9

N-(benzyl)-N'-(isobutyl)sulfamide 9

White powder. Yield: 22%. M.p.: 133°C. TLC: R_f = 0.73 (AcOEt / *n*-Hexane: 6/4). ¹H NMR (400 MHz, CDCl₃, δ, ppm): 1.06 (d, 6H, 2CH₃); 2.00 (m, 1H, CH(CH₃)₂); 2.65 (d, 2H, CH₂-N); 4.15 (d, 2H, J = 5.99 Hz, CH₂-Ph); 4.28 (s, 1H, NH-iBu); 4.47 (s, 1H, NH-Bn); 7.30 (m, 5H, ArH). MS (NOBA, FAB > 0): 627 [M + H]⁺. Anal. calcd for C₁₁H₁₈N₂O₂S: C, 54.51%; H, 7.48%; S, 13.23%; found: C, 54.43%; H, 7.63%; S, 13.31%.

RESULTS AND DISCUSSION**Synthesis**

In this work, we exploit a method developed in previous works¹⁶⁻¹⁷, for the preparation of unsymmetrical sulfamides derived of primary amines. Unsymmetrical and symmetrical sulfamides can be prepared by the direct addition of sulfonyl chloride to a mixture of two primary amines in cyclohexane or hexane at 0°C. As discussed in our previous work, we have also obtained three compounds: two symmetric sulfamides and the mixed sulfamide. TLC reveals unsymmetrical sulfamide formation and it is located in the middle between the first and the second symmetric sulfamides. In this paper, we are interested to the separation of dissymmetric sulfamides in order to estimate their antibacterial activity.

In the ¹H NMR spectra all synthesized compounds revealed the presence of amino group protons signals as singlet around 4.26 - 4.45 ppm, 4.26 - 4.47 ppm and 4.26 - 4.50 ppm for the thiophene, benzyl and pyridine series, respectively. Mass spectrometry analysis validated the structure of the examined derivatives. In all compounds, fragmentation peaks confirmed the structure of the analyzed molecules.




Fig. 1: Antibacterial activity against Gram- and Gram+ strains

In Vitro Antibacterial Activity

The title compounds containing thiophene (Series 1), pyridine (Series 2) and benzyl (Series 3) moieties were screened for their *in vitro* antibacterial activity against *Enterobacteriaceae* and *Staphylococcus aureus* by using disk diffusion and micro dilution methods. The zones of inhibition and the minimum inhibitory concentrations obtained by the synthesized compound were furnished in Table 1. The results of preliminary bioassay of the synthetic compounds revealed that the majority of the synthesized compounds were fairly active against all tested bacteria. As shown in the Table 1 and figure 2, the synthesized compounds exhibited a broad spectrum of activity with MIC values 4 - 512 µg/mL against *Enterobacteriaceae* and *Staphylococcus aureus* strains with MIC vary between 2 and 512 µg/ml.

It was evident From Table 1 That the compound **2** of Series **1** (thiophene moiety) containing isopentyl substituted have exhibited higher activity than the compound **3** containing substituted isobutyl moiety followed by the compound **1** containing substituted *tert*-butyl moiety, their MIC values were (4 - 32 - 64 µg/mL) against *Enterobacteriaceae* and (2 - 4 - 16 µg/mL) against *Staphylococcus aureus*, respectively.

Series 2 (pyridine moiety), among compounds **4**, **5**, and **6** derived from pyridine, compound **5** was the most potent among their series with MIC equal to 64 µg/ml (31mm) , while the compounds **4** and **6** showed moderate antibacterial activity with a MIC value equal to 128 - 512 µg/ml against *Staphylococcus Aureus* and *Enterobacteriaceae*.

Series 3 (benzyl moiety), compounds **7** and **9** with *tert*-butyl and isobutyl as alkyls, respectively showed moderate activity, their MIC values were (128 - 512 µg/ml), Whereas compound **8** which also contain a benzyl moiety but with isopentyl alkyl was the most active among this series with a MIC value equal to 32 - 64 µg/ml towards *Staphylococcus aureus* and *Enterobacteriaceae*, respectively.

In conclusion, Antibacterial Activity studies indicate that isopentyl substituted sulfonamides

of each series were more active than the other members.

Theoretical calculation

The highest occupied molecular orbital (HOMO), the lowest unoccupied molecular orbital (LUMO) and HOMO and LUMO energy gaps for compounds 1-9 calculated at DFT level in the 6-31G basis set. The eigenvalues of LUMO and HOMO and their energy gap reflect the chemical activity of the molecule. LUMO as an electron acceptor represents the ability to obtain an electron, while HOMO as an electron donor represents the ability to donate an electron. The smaller the LUMO and HOMO energy gaps, the easier it is for the HOMO electrons to be excited; the higher the HOMO energies, the easier it is for HOMO to donate electrons; the lower the LUMO energies, the easier it is for LUMO to accept electrons. A hard molecule has a large energy gap, and a soft molecule has a small gap.

From theoretical calculations established, it was found that the molecule **4** has the lowest energetic gap ($\Delta E_{\text{gap}} = 5.54$ eV), so it is the softest molecule and it is the best to be easily excited by against, the molecule **3** has the highest energy gap

($\Delta E_{\text{gap}} = 5.81$ eV), so it is the hardest molecule. Molecule **1** has the highest HOMO energy ($E_{\text{HOMO}} = -6.16$ eV) that allows him to be the best electron donor molecule; on the other hand the molecule **6** has the lowest LUMO energy ($E_{\text{LUMO}} = -0.863$ eV) that allows it to be the best electron acceptor molecule.

Two important properties of any molecule (M) are its gas-phase ionization potential (I) and its electron affinity (A). The determination of I and A allows the absolute electronegativity (χ) and absolute hardness (ζ) parameters for M to be calculated. In the most common case, I and A are related to the one-electron orbital energies of the HOMO and LUMO, respectively. Then (I—A) is simply the difference in energy between the HOMO and the LUMO. Soft molecules have a small energy gap. Low 'I' creates a better electron donor and large 'A' makes a better electron acceptor. For almost all of the commonly used exchange-correlation functional, the HOMO and LUMO energy are not close to the exact IP and EA respectively but, excellent linear correlation relationship exists between HOMO energies and calculated IP and also between the negative of the LUMO energies and calculated EA. Therefore based on these linear correlation relationships, the calculated HOMO and LUMO energies can be used to semi quantitatively estimate the ionization potential and electron affinity.

Considering the above, compound **6** has the greater electron affinity value ($A = 0.86$ eV) which indicate that it is the best electron acceptor. Compound **1** has the lowest ionization potential value

Table 1: Zones Of Growth Inhibition And MIC Values Of The Compounds 1-9

		<i>Bacterial strains Enterobac Staphylococcus</i>	
		<i>teriaceae</i>	<i>aures</i>
1	DZI (mm)	20	24
	MIC ($\mu\text{g/ml}$)	64	16
2	DZI (mm)	18	22
	MIC ($\mu\text{g/ml}$)	4	2
3	DZI (mm)	18	20
	MIC ($\mu\text{g/ml}$)	32	4
4	DZI (mm)	33	36
	MIC ($\mu\text{g/ml}$)	512	256
5	DZI (mm)	31	31
	MIC ($\mu\text{g/ml}$)	64	64
6	DZI (mm)	30	30
	MIC ($\mu\text{g/ml}$)	256	128
7	DZI (mm)	14	18
	MIC ($\mu\text{g/ml}$)	512	256
8	DZI (mm)	13	16
	MIC ($\mu\text{g/ml}$)	64	32
9	DZI (mm)	13	13
	MIC ($\mu\text{g/ml}$)	512	128

Table 2: Some Energetic Properties Of Compounds 1-9

Comp.	E_{HOMO} (eV)	E_{LUMO} (eV)	ΔE_{gap} (eV)	I (eV)	A (eV)
1	-6.168	-0.389	5.778	6.168	0.389
2	-6.218	-0.407	5.811	6.218	0.407
3	-6.229	-0.411	5.818	6.229	0.411
4	-6.375	-0.834	5.541	6.375	0.834
5	-6.476	-0.857	5.619	6.476	0.857
6	-6.497	-0.863	5.634	6.497	0.863
7	-6.198	-0.241	5.957	6.198	0.241
8	-6.296	-0.261	6.035	6.296	0.261
9	-6.317	-0.268	6.049	6.317	0.268

($I = 6.16$ eV) which indicate that it is the best electron donor.

Theoretical calculations were performed in order to investigate physico-chemical properties that may be related to the antimicrobial action of the studied compounds. The chemical reactivity of the molecular systems has been determined by the conceptual density functional theory³⁹. Electronegativity (χ), chemical potential (μ), global hardness (η), global softness (S) and electrophilicity index (ω) are global reactivity descriptors and are highly successful in predicting global reactivity trends. A property of interest in this study was the global electrophilicity index, which may give some insight on the biological activity of compounds.

All these parameters for compounds 1-9 have been listed in Table 3. According to these parameters, the chemical reactivity varies with the structural of molecules. Chemical hardness (softness) value of compound 4 is lesser (greater) among all the molecules. Thus, compound 4 is found to be more reactive than all the molecules. Compound 6 possesses higher electronegativity value than all compounds so; it is the best electron acceptor.

The values of ω for compounds 1-9 indicate that they are three series classified in the order, series of pyridine, thiophene and benzyl, successively. The pyridine group has the high value of electrophilicity index which, shows that the compounds of this group are a strong electrophiles than the thiophene and benzyl groups respectively.




Fig. 2: The minimum inhibition concentration of compounds 1-9




Fig. 3: The inhibition zones of compounds 1-9




Fig. 4: Frontier orbitals and MESP surfaces for compounds 2, 5 and 8

Table 3: The Calculated Quantum Chemical Parameters Of Compounds 1-9

Comp.	μ (eV)	χ (eV)	η (eV)	S(eV)	ω (eV)
1	-3.278	3.278	2.889	0.173	1.859
2	-3.312	3.312	2.905	0.172	1.887
3	-3.320	3.320	2.909	0.171	1.885
4	-3.604	3.604	2.770	0.180	2.338
5	-3.666	3.666	2.809	0.178	2.392
6	-3.680	3.680	2.817	0.177	2.397
7	-3.219	3.219	2.879	0.173	1.793
8	-3.278	3.278	3.017	0.166	1.784
9	-3.292	3.292	3.024	0.165	1.788

CONCLUSION

In conclusion, a series of novel unsymmetric linear sulfonamides (1-9) were synthesized and their antibacterial activities were evaluated against some bacterial strains. The HOMO, LUMO and MESP surfaces are analyzed to discuss the chemical reactivity patterns in the molecules. A number of reactivity parameters have been calculated to further explain their chemical reactivity. It was observed that within each series, compounds 2, 5 and 8 containing isopentyl alkyl showed the highest biological activity. These new data of these compounds might be helpful in the future development of sulfonamide analogues as novel antibacterial agents.

ACKNOWLEDGMENTS

This work was generously supported by the (General Directorate for Scientific Research

and Technological Development, DGRS-DT) and Algerian Ministry of Scientific Research.

REFERENCES

- Hansch C.; Sammes P. G.; Taylor J. B. *Comprehensive Medicinal Chemistry*, Pergamon Press: Oxford **1990**, 2, Chapter 7.1.
- Vree, T. H. *Clinical Pharmacokinetics of Sulfonamides and Their Metabolites*. Karger: *Basel*, **1987**, 37.
- Karale , B. K.; Takate, S. J.; Salve, S. P.; Zaware, B. H. and Jadhav S. S. *Orient. J. Chem.*, **2015**, 31, 307-315.
- Supuran, C. T.; Scozzafava, A. *Curr. Med. Chem.* **2001**, 1, 61-97.
- Maren, T. H. *Annu. Rev. Pharmacol. Toxicol.* **1976**, 16, 309-327.
- Boyd, A. E. *Diabetes* **1988**, 37, 847-850.
- Thornber, C. W. *Chem. Soc. Rev.* **1979**, 8, 563-580.
- Felegari, Z. *Orient. J. Chem.*, **2014**, 30, 1865-1875.
- Ouarna, S.; K'tir, H.; Lakrout, S.; Ghorab, H.; Amira, A.; Aouf, Z.; Berredjem, M.; Aouf, N. E. *Orient. J. Chem.*, **2015**, 31, 913-919.
- Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; et al. Gaussian 09, Revision C.01; Gaussian Inc.: Wallingford, CT, USA, 2010.
- Schlegel, H. B. *J. Comput. Chem.* **1982**, 3, 214-218.
- Ditchfield, R.; Hehre, W. J.; Pople, J. A. *J. Chem. Phys.* **1971**, 54, 724-728.
- Dennington, R.; Keith, T.; Millam, J. GaussView, Version 5, Semicem Inc., Shawnee Mission, KS, **2009**.
- CLSI document M07-A9. Wayne, PA: Clinical and Laboratory Standards Institute; **2012**.
- Venkateswara Rao, J.; Krishna Reddy, V.; Bhavani, R.; Bhavani, B. *Orient. J. Chem.*, **2015**, 31, 2253-2258.
- Bendjeddou, A.; Djebbar, H.; Berredjem, M.; Hattab, Z.; Regainia, Z.; Aouf, N. E. *Phosphorus, Sulfur and Silicon.* **2006**, 181, 1351-1362.
- Bendjeddou, A.; Djeribi, R.; Regainia, Z.; Aouf, N. E. *Molecules.* **2005**, 10, 1387-1398.